Investor Presentaiton
30
Investor presentation
Full year 2022
Novo NordiskⓇ
Pipeline supports significant growth opportunities across all four
strategic focus areas
PHASE 1
NN1845 - GSI
NN1471 - Pumpinsulin
NN9041 - DNA Immunotherapy
NN9541 - Oral GLP-1/GIP co-agonist
NN9917 - SemaDapa FDC
NN9904 Once weekly oral sema
NN9847 - Oral Amycretin
DCR-AUD¹
NN6020
NN6582 - - LXR(a)
NN6581
MARC1
PHASE 2
NN9389
NN9388
-
FDC Sema - OW GIP
Cagrisema
NN9775 PYY 1875 analogue
NN7533 - Ndec
NN9931 Gilead NASH
NN9500 FGF-21 NASH
NN6021 Belcesiran
-
-
NN6019-ATTR Cardiomypathy
PHASE 3
NN1535
Icosema
NN1436 Insulin Icodec
NN9924 Oral Semaglutide 25 and 50 mg
NN9838 Cagrisema
NN9932 - Oral Semaglutide 50mg obesity²
NN9931 Semaglutide NASH
NN6535 - Semaglutide in AD
NN6018 Ziltivekimab
-
NN7769 - Mim8
NN7535- Etavopivat
Other PHASE 3 trials
SOUL - Oral semaglutide 14.0 mg CVOT
FOCUS Semaglutide 1.0 mg in diabetic retinopathy
FLOW-Semaglutide 1.0 mg in CKD
STRIDE - Semaglutide 1.0 mg in PAD
STEP-Semaglutide 2.4mg in HFPEF
SELECT Semaglutide 2.4mg in obese population
SUBMITTED
APPROVED
NN8640-Sogroya® - QW GHD³
TresibaⓇ
-
NN7415 Concizumab4
XultophyⓇ
NN7022
Nedosiran
LevemirⓇ
Ryzodeg
NovoMixⓇ
FiaspⓇ
NovoRapidⓇ
RybelsusⓇ
OzempicⓇ6
VictozaⓇ
WegovyⓇ
SaxendaⓇ
NovoSeven
NovoEight®
Ⓡ
EsperoctⓇ
NovoThirteenⓇ
Refixia
NorditropinⓇ
SogroyaⓇ5
Diabetes care
Obesity care
Rare blood disorders
Rare endocrine disorders
Other serious chronic diseases
1 Dicerna-Alcohol Use Disorder; 225 mg trial also initiated; 3 Study conducted in growth hormone disorders; 4 Submitted to EU/US/JP in HwI; 5 Approved in the EU, the US and Japan, for adult growth hormone disorder, 6 higher doses of injectable semaglutide (8
mg and 16 mg) tested in phase 2; PYY: Peptide YY; QW: Once-weekly; mAb: monocolonal antibody; GDF15: Growth differentiation factor 15; Sema: Semaglutide; FGF-21: Fibroblast growth factor 21; LAI: Long-acting insulin; GHD: Growth hormone disorder; GSI:
Glucose Sensitive Insulin; HFPEF: heart failure with preserved ejection fraction; AD: Alzheimer's Disease; FDC; Fixed-dose combination; NASH: Nonalcoholic Steatohepatitis; US: United States; JP: Japan; PAD: Peripheral arterial disease; CKD: chronic kidney diseaseView entire presentation